Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T, Watanabe A, Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H.
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.
Cell Stem Cell. 2013 Apr 4;12(4):487-96.
Please login to recommend the paper.
Make a Comment
This paper adds to a growing number of publications using iPSCs to study AD-related cellular phenotypes in vitro (Qiang et al., 2011; Israel et al., 2012; Yagi et al., 2011; Shi et al., 2012). It is reassuring to see so many labs independently finding robust phenotypes in their various cell lines. The fact that these cells converge on similar phenotypes with respect to altered APP processing is interesting, and I think we can now be confident that patient-derived neurons are a good model for AD pathogenesis. The next step is to determine the mechanism(s) by which these observed differences in APP processing are leading to cell death in AD. I hope we'll start to see reports where patient-derived neurons are being used to uncover novel disease mechanisms.
For me, the most interesting aspect of this paper is the differential responsiveness to DHA. Understanding why certain cell lines are responsive to treatments whilst others are not could ultimately have implications in the clinic: The success of a particular treatment could depend on patients being "subtyped" appropriately. However, given that this study only examines cells from two familial patients and two sporadic patients, it is difficult to draw any firm conclusions in that respect without expanding this study to include more patients.
Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L, Aubry L, Vanti WB, Moreno H, Abeliovich A.
Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons.
Cell. 2011 Aug 5;146(3):359-71.
Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS.
Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells.
Nature. 2012 Feb 9;482(7384):216-20.
Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, Yamanaka S, Okano H, Suzuki N.
Modeling familial Alzheimer's disease with induced pluripotent stem cells.
Hum Mol Genet. 2011 Dec 1;20(23):4530-9.
Shi Y, Kirwan P, Smith J, Maclean G, Orkin SH, Livesey FJ.
A human stem cell model of early Alzheimer's disease pathology in Down syndrome.
Sci Transl Med. 2012 Mar 7;4(124):124ra29.
This extensive, collaborative study brings new evidence supporting the idea that the pathologically relevant amyloid-β peptide (Aβ) is produced and aggregates in compartments in the neuronal soma, including the endosomes, lysosomes, and the endoplasmic reticulum (ER). The generation and oligomerization of Aβ in the ER does not come as a surprise, given that the ER is one of the centers of stress response of the cell. Many types of stress—oxidative, improper protein folding, or the accumulation of proteins in the soma due to impeded transport along the secretory pathway—appear to be sensed by the ER. The ER response, which is geared to relieve the stress-related pathology, is currently widely studied.
The idea that Aβ is generated in the soma, where it accumulates and oligomerizes, is not new (1-3). Also, the idea that stress leads to the generation, accumulation, and oligomerization of Aβ in the endoplasmic reticulum has been previously proposed. For example, we reported that enhanced cleavage of APP in the ER, followed by accumulation and oligomerization of Aβ inside the ER, represents the specific response of the neuron to impeded axonal transport (4)—a situation that becomes an issue in old age (5). It is also likely that part of the oligomeric Aβ produced either in the ER or in the somatic endosomes escapes from these compartments and is transported into neurites, accumulating at their distal tips (2). Although some Aβ could certainly be generated and aggregated at the synapse, emerging evidence, such as that provided by this study, highlights the possibility that pathologically relevant Aβ oligomers are produced in the neuronal soma in neurons affected by Alzheimer's disease. This intraneuronal Aβ could be released in the extracellular space either by cell death or by other mechanisms operating in neurons, such as externalization via exosomes. The field of Alzheimer’s disease is eagerly awaiting new developments in this direction.
Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM, Doms RW.
Alzheimer's A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells.
Nat Med. 1997 Sep;3(9):1021-3.
Muresan Z, Muresan V.
Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells.
Mol Cell Biol. 2006 Jul;26(13):4982-97.
Skovronsky DM, Doms RW, Lee VM.
Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture.
J Cell Biol. 1998 May 18;141(4):1031-9.
Muresan V, Muresan Z.
A persistent stress response to impeded axonal transport leads to accumulation of amyloid-β in the endoplasmic reticulum, and is a probable cause of sporadic Alzheimer's disease.
Neurodegener Dis. 2012;10(1-4):60-3.
Muresan V, Muresan Z.
Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?.
Future Neurol. 2009 Nov 1;4(6):761-773.
To make a comment you must login or register.